These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33316195)

  • 1. In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors.
    Liakos A; Tsapas A; Bekiari E
    Ann Intern Med; 2020 Dec; 173(12):JC70. PubMed ID: 33316195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis.
    Dawwas GK; Flory JH; Hennessy S; Leonard CE; Lewis JD
    Diabetes Care; 2022 Apr; 45(4):919-927. PubMed ID: 35147696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study.
    Douros A; Lix LM; Fralick M; Dell'Aniello S; Shah BR; Ronksley PE; Tremblay É; Hu N; Alessi-Severini S; Fisher A; Bugden SC; Ernst P; Filion KB;
    Ann Intern Med; 2020 Sep; 173(6):417-425. PubMed ID: 32716707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes.
    Griffin TP; Dinneen SF
    Ann Intern Med; 2020 Oct; 173(8):JC40. PubMed ID: 33075260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.
    Fralick M; Schneeweiss S; Patorno E
    N Engl J Med; 2017 Jun; 376(23):2300-2302. PubMed ID: 28591538
    [No Abstract]   [Full Text] [Related]  

  • 7. The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus.
    van Hulten V; Driessen JHM; Starup-Linde JK; Al-Mashhadi ZK; Viggers R; Klungel OH; Souverein PC; Vestergaard P; Stehouwer CDA; van den Bergh JP
    Diabetes Obes Metab; 2023 Nov; 25(11):3235-3247. PubMed ID: 37503747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
    Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
    Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus.
    Fralick M; Colacci M; Thiruchelvam D; Gomes T; Redelmeier DA
    Diabetes Obes Metab; 2021 Apr; 23(4):950-960. PubMed ID: 33336894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of sodium glucose co-transporter-2 inhibitors with risk of diabetic ketoacidosis among hospitalized patients: A multicentre cohort study.
    Sarma S; Hodzic-Santor B; Raissi A; Colacci M; Verma AA; Razak F; Højbjerg Lassen MC; Fralick M
    J Diabetes Complications; 2024 Sep; 38(9):108827. PubMed ID: 39096768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis.
    Hamblin PS; Wong R; Bach LA
    Med J Aust; 2021 Feb; 214(2):94-94.e1. PubMed ID: 33349919
    [No Abstract]   [Full Text] [Related]  

  • 13. Sodium-glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis.
    Meyer EJ; Thiruvenkatarajan V; Jesudason D
    Med J Aust; 2021 Feb; 214(2):93-93.e1. PubMed ID: 33349926
    [No Abstract]   [Full Text] [Related]  

  • 14. Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohorts.
    Rebordosa C; Thomsen RW; Tave AK; Madsen M; Beachler DC; Martinez D; Garcia-Esteban R; Plana E; Tormos A; Farsani SF; Perez-Gutthann S; Pladevall-Vila M
    Diabetes Obes Metab; 2024 Apr; 26(4):1291-1304. PubMed ID: 38234181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose cotransporter-2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database.
    Takeuchi Y; Kumamaru H; Hagiwara Y; Matsui H; Yasunaga H; Miyata H; Matsuyama Y
    Diabetes Obes Metab; 2021 Jun; 23(6):1379-1388. PubMed ID: 33606891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors].
    Valek R; Von der Mark J
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):145-148. PubMed ID: 27221094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic ketoacidosis with SGLT2 inhibitors.
    Musso G; Saba F; Cassader M; Gambino R
    BMJ; 2020 Nov; 371():m4147. PubMed ID: 33184044
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.
    Han SJ; Ha KH; Lee N; Kim DJ
    Diabetes Obes Metab; 2021 Mar; 23(3):682-691. PubMed ID: 33236515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
    Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two alcoholic liver cirrhosis patients developed diabetic ketoacidosis after SGLT2 inhibitors-prescription.
    Chao HY; Kornelius E
    J Formos Med Assoc; 2020 Dec; 119(12):1886-1887. PubMed ID: 32690358
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.